Peter Dritschilo
President at SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Net worth: 3 483 $ as of 2024-05-30
Profile
Peter Dritschilo currently works at Shuttle Pharmaceuticals, Inc., as President & Chief Operating Officer from 2012 and Shuttle Pharmaceuticals Holdings, Inc., as President & Chief Operating Officer.
Mr. Dritschilo received his undergraduate degree from Georgetown University and Masters Business Admin degree from The GW School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-20 | 6,560 ( 0.04% ) | 3 483 $ | 2024-05-30 |
Peter Dritschilo active positions
| Companies | Position | Start |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | President | 2012-12-17 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | President | 2012-11-30 |
Training of Peter Dritschilo
| Georgetown University | Undergraduate Degree |
| The GW School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
| Shuttle Pharmaceuticals Holdings, Inc. |
- Stock Market
- Insiders
- Peter Dritschilo
